MLTX DEADLINE: MoonLake Immunotherapeutics Investors with Losses are Notified to Contact BFA Law before December 15 Securities Class Action Deadline

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab, leading to significant stock price declines after disappointing trial results [2][4][5][7][8]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [5]. Group 2: Allegations and Legal Action - The lawsuit claims that MoonLake and its executives violated federal securities laws by providing misleading information about the clinical benefits of sonelokimab [2][4][6]. - The complaint is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in MoonLake common stock [4]. Group 3: Clinical Trial Results and Impact - MoonLake reported disappointing results from the VELA Phase 3 trials on September 28, 2025, with VELA-2 failing to meet its primary endpoint, raising doubts about the drug's regulatory approval and commercial viability [8]. - Following the announcement, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [8].